Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Shape Pharmaceuticals, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
The Leukemia and Lymphoma Society
Therapeutics, Inc.
Veristat, Inc.
PPD
Information provided by (Responsible Party):
Shape Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01433731
First received: September 9, 2011
Last updated: February 12, 2014
Last verified: February 2012
  Purpose

The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL.


Condition Intervention Phase
Lymphoma, T-Cell, Cutaneous
Drug: SHP-141
Drug: placebo fo SHP-141
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Resource links provided by NLM:


Further study details as provided by Shape Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Lesion severity using CAILS (Composite Assessment of Index Lesion Severity) [ Time Frame: Weekly through day 28 (days 1, 7, 14, 21, 28) and again day 42 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 48
Study Start Date: September 2011
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SHP-141
Histone deacetylase inhibitor
Drug: SHP-141
topical gel
Placebo Comparator: placebo Drug: placebo fo SHP-141
topical gel

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histopathologically confirmed CTCL; a documented verifiable biopsy report is required.
  • Documented clinical Stage IA, IB, or IIA CTCL.
  • Skin lesion involvement of at least 3% of BSA accessible for topical application of study drug and biopsy.
  • ECOG performance status of 0-2.

Exclusion Criteria:

  • CTCL with histologic evidence of folliculotropic variant or large cell transformed CTCL.
  • Severe pruritus requiring systemic or topical treatment.
  • Palpable lymph node ≥1.5 cm in diameter (unless the lymph node has been biopsied and has been designated as Stage IA-IIA disease).
  • Coexistent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix (CIN 3), papillary or follicular thyroid cancer that has been treated curatively, or prostate cancer that has been treated curatively).
  • Any prior history of a hematologic malignancy (other than CTCL).
  • History of or current major renal, hepatic, gastrointestinal, pulmonary, cardiovascular, genito-urinary or hematological disease, CNS disorders, infectious disease or coagulation disorders as determined by the Investigator.
  • Evidence of active Hepatitis B or C or HIV.
  • Circulating atypical cells >5%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01433731

Locations
United States, California
Stanford University
Stanford, California, United States, 94305
United States, Illinois
Northwestern University Dept of Dermatology
Chicago, Illinois, United States, 60611
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Shape Pharmaceuticals, Inc.
The Leukemia and Lymphoma Society
Therapeutics, Inc.
Veristat, Inc.
PPD
Investigators
Principal Investigator: Joan Guitart, MD Northwestern University
  More Information

No publications provided

Responsible Party: Shape Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01433731     History of Changes
Other Study ID Numbers: SHP-141-001
Study First Received: September 9, 2011
Last Updated: February 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Shape Pharmaceuticals, Inc.:
CTCL
Cutaneous T-Cell Lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014